From Communications Strategist to Purpose-Built Leader

Craig began his Boston journey after relocating from Washington, D.C., to join Feinstein Kean Healthcare — a leading consultancy in the life sciences space — as the chosen successor to a founding CEO. There, he furthered his gift for translating scientific and commercial complexity into clear, compelling strategy and narratives. More than a decade later, Feinstein Kean was folded into a holding company, and its name was retired. However, Craig’s Boston roots and passion for guiding life science companies only deepened from there.

Encouraged by his Boston innovation networks, he eventually struck out on his own, founding Rithm Health, a consultancy that advises biotech, digital health, and rare disease companies. It quickly became clear that this wasn’t a sideline gig; it was a mission: supporting companies seeking revenue and impact.

Advisory Leader in the Boston Biopharma Ecosystem

For some 25 years, Craig has advised early- and mid-stage teams—across health categories—on strategy, business development, communications, and patient engagement. His counsel regularly integrates a responsible business mindset and empathy-infused decision-making, often behind the scenes but profoundly influential.

It’s among the many reasons he was invited onto the board of Global Genes years ago and later extended into advisory roles across rare disease nonprofits and biotech initiatives (including the Fibrolamellar Cancer Foundation).

Craig’s long-standing volunteerism at Global Genes evolved into formal leadership: he chaired the Corporate Alliance and shaped the organization’s strategy for diagnostic and treatment equity, clinical trial access, and diversity.  In 2020, he accepted the role of interim CEO, stepping in at a time of transition purely to serve the rare-disease community. Through the next few years, he helped scale the organization globally while preserving its high-touch culture and mission-aligned focus.

Under Craig, the organization prioritized community capacity-building, integrated, personalized service through RARE Concierge, and connecting patients to diagnosis, trials and support —rather than duplicating work in policy or research. His leadership culminated in the seamless reintegration of RARE‑X, bolstering data sharing and patient-driven research approaches under the Global Genes umbrella.

Launching the Orphan Therapeutics Accelerator

Craig built on that experience by founding the Orphan Therapeutics Accelerator (OTXL) in June 2024. Recognizing that many Phase 1/2 rare disease therapies stall—not from scientific failure, but because of funding or infrastructure gaps—he designed OTXL as a nonprofit biotech that sources shelved ultra‑rare programs and drives them forward through development via Orphan ClinDevNet—a coalition of partners delivering low-cost, AI‑enabled services for clinical trials, manufacturing, regulatory readiness and commercialization.

In the traditional biopharma model, promising compounds are often shelved—not due to scientific failure, but because their potential market size is considered too small to justify the cost and complexity of development. This is especially true in the rare and ultra-rare disease space, where patient populations may number in the hundreds or low thousands.

Larger pharmaceutical companies, focused on ROI and portfolio prioritization, frequently set aside these “orphaned” therapies despite early efficacy signals. Craig recognized that these shelved molecules represented more than business decisions; they represented delayed or denied hope for real patient communities. His insight was to operationalize around these forgotten assets, championing their advancement through an entrepreneurial nonprofit model that combines development efficiency, community partnership, novel commercialization pathways, and mission-driven focus.

By aligning with rare disease advocates and building a collaborative ecosystem, Craig’s Orphan Therapeutics Accelerator brings new life to therapies that might never see the clinic.

Leading Founding Members include Chiesi and BIAL, with operations supported by Landmark Bio, Uncommon Cures®, Viralgen, DVLP Medicines, and Vibe Bio. OTXL aims to be financially self‑sustaining within 4–6 years, reinvesting revenue from commercialized programs to support growing rare disease pipelines.

Though now operating globally, Craig maintains an active advisory presence in Boston’s biotech and healthtech sectors. He contributes strategy, governance insight, and rare-disease expertise to companies and nonprofits—and mentors emerging leaders bridging science, patient advocacy, and enterprise.

He’s also appeared at conferences such as Advanced Therapies USA 2025, reflecting his growing profile in the global gene-therapy and pricing-access discussion space.

What We Can All Learn from Craig’s Journey

Craig’s story—spanning executive leadership, consulting firm founding, nonprofit board, interim CEO, and biotech founder—offers five powerful lessons:

1. A compelling narrative is a critical component of strategic leadership. Translating complexity into resonance is more than marketing—it shapes how people connect, invest, and act.

• Empathy drives innovation. Patient insight isn’t an add-on; it’s the organizing principle of strategy.
  
  
• New structures empower neglected science. OTXL’s nonprofit biotech model demonstrates how shelved assets can become viable through purpose-aligned stewardship.

• Community builds momentum. Boston’s collaborative ecosystem supported Craig’s leaps—from Feinstein Kean to independent consultancy—amplifying impact.

• Purpose provides continuity. Across roles, his north star has remained: bring science closer to patients in sustainable, human-focused ways.

Craig Martin reflects what I’ve learned about leadership in health innovation: that proximity—to patients, communities, and complexity—makes the difference. As he told me during our conversation: “The science is often there. The challenge is translation—moving from discovery to delivery.”

In every role, in Boston and beyond, Craig is focused on that translation—one program at a time, one community at a time—with purpose at the center.

The post Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients appeared first on Medika Life.

He is a second-generation physician who prefers to be called by his first name, honoring his father, “the original Dr. Grossmann.”  In his own right, he’s a trailblazer at the nexus of surgical care and innovation. Born in Caracas, Venezuela and carrying forward his family’s medical legacy, he completed his surgical residency in Ann Arbor, Michigan, before establishing his practice in New England, serving as a general, trauma, advanced laparoscopic, and robotic surgeon at Portsmouth Regional Hospital in New Hampshire and Eastern Maine Medical Center.

Rafael is frequently linked to his groundbreaking use of Google Glass during surgery. But to define him by that singular innovation is to miss the deeper force driving his work: an unwavering belief that technology must serve—not supplant—the doctor–patient relationship. In recent interviews and longstanding contributions across digital health platforms, Rafael shares an increasingly urgent message: humility and empathy are not soft skills of the past—they are foundational elements of the future.

Proximity Over Performance
Rafael’s approach to technology is both deliberate and human-centered. He integrates AI, extended reality, and telehealth into care environments with one goal: to foster proximity between healer and patient. Whether bringing loved ones into ICU rooms through virtual tools, using augmented reality to teach medical trainees, or deploying wearables to enhance surgical insight, his purpose is consistent: technology must deepen the human connection.

“If the technology doesn’t enhance the connection between physician and patient,” Dr. Grossmann notes, “it has no role in care.”

That conviction reflects a broader truth in modern medicine: innovation must be guided by intention. The impact of a new tool is not measured by its complexity, but by its capacity to sharpen listening, expand compassion, and build trust. In this view, humility is not an abstract virtue—it is a clinical competency.

Humility as a Clinical Skill
While empathy is increasingly recognized as a measurable component of quality care, humility remains underappreciated. Yet humility—the ability to acknowledge limits, listen fully, and elevate the patient’s needs—may be one of the most critical skills a clinician can develop.

Rafael challenges medical education to do more than train for outcomes; he calls for cultivating presence. In trauma settings and academic halls alike, he models humility not as passivity, but as active, intentional leadership. It takes courage, he says, to be honest with patients—not just about diagnoses, but about uncertainty.

“The best medicine,” he reflects, “comes from presence, not only performance.” In high-tech environments where algorithms analyze and recommend, the clinician’s humility may be the most human—and healing—intervention available.

Empathy, Elevated by Innovation
To Rafael, empathy and innovation are not opposites. When used wisely, technology can extend—not replace—the clinician’s presence. Telemedicine platforms become conduits for comfort. Immersive simulations train for compassion. Data becomes dialogue when interpreted with care.

This mindset is especially important now. Patients today may have unprecedented access to information, yet they often feel unseen. In an age of instant answers, the experience of being truly heard remains rare. Rafael reminds health-sector leaders and policymakers that no system—however advanced—can succeed if it forgets the people it was designed to serve.

Clinicians stand at a crossroads as health delivery accelerates toward predictive analytics and AI-driven decisions. Technology offers an undeniable opportunity: greater access, improved accuracy, and better outcomes. But these advances must be matched by a return to the timeless principles of great medicine—empathy, humility, and presence.

Rafael’s work represents a rare blend of innovation and introspection. His willingness to explore the boundaries of digital medicine is matched by a steadfast insistence that patients remain at the center. The future of care, he contends, won’t be defined by who uses the most sophisticated technology, but by who uses it to deepen human connection.

Rafael is not focused on being remembered for the tools he introduced. He hopes to be known for something quieter: helping patients and clinicians feel seen, heard, and supported.

In an era when health systems are rethinking priorities, medical schools are reassessing competencies, and companies are racing to redefine care delivery, the voices of clinicians like Rafael’s matter more than ever. Humility, after all, is not the opposite of expertise—it is its most authentic expression.

The post “Humility” Is Cutting-Edge Medicine: What a Physician Innovator Teaches Us About Patient-Centered Care appeared first on Medika Life.